Kornimate/medical-research-clean huggingface dataset:
clozapine versus chlorpromazine for treatment-unresponsive schizophrenia

Conditions: Schizophrenia

Summary: this study will examine the physical response to clozapine or chlorpromazine in people with schizophrenia that has not improved with treatment.

this is a longitudinal double-blind 12-week study of the clinical and biochemical response to clozapine or chlorpromazine in a group of treatment-refractory schizophrenic patients. the study has 4 phases: (1) a recruitment period; (2) a period of discontinuation of psychotropic medication; (3) a drug-washout period; and (4) a 12-week double-blind trial of clozapine or chlorpromazine.

Eligibility criteria:
inclusion criteria: * 19-60 years of age * diagnosis of schizophrenia * bprs score \> 50 * clinical global impressions rating \> 4 * one of the following: bprs items rated greater than or equal to 4, conceptual disorganization, suspiciousness, hallucinations, unusual thought content. * at least 2 six-week trials of different neuroleptics given at a dosage equivalent to at least 600 mg per day of chlorpromazine or at least 1 eight-week trial of a neuroleptic given at a dosage equivalent to at least 800 mg per day of chlorpromazine. * the patient (or the patient's authorized legal representative) must understand the nature of the study and sign the informed consent. exclusion criteria: * history of substance dependence within the past 2 months * major medical problems precluding the use of clozapine * pregnancy or lactation * a serious suicide/homicide risk

Keywords: clozapine chlorpromazine schizophrenia biochemistry
infusion laboratory: protocol 3 (risperidone) - 4

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate clinical safety issues pertaining to risperidone, to cocaine and to its interaction, and to determine how pretreatment with risperidone modifies the subjective as well as physiological effects of cocaine.


Eligibility criteria:
inclusion criteria: m/f ages 21-50. meet dsm-iv criteria for cocaine dependence. agree to conditions of the study and sign informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nuring women. dependence on etoh or benzodiazepines or other sedative/hypnotics. acute hepatitis. other medical condtions that deem participation to be unsafe.

Keywords: cocaine dependence
assessment of sleep and sleep disruptors in adolescents with type 1 diabetes

Conditions: Type 1 Diabetes; Insufficient Sleep

Summary: the goal of this study is to identify causes of insufficient sleep and sleep disruptors in adolescents with type 1 diabetes. for this study, adolescents will wear an actigraphy watch and complete sleep diaries for seven days. on completion of the seven days, they will complete several questionnaires regarding sleep, fear of hypoglycemia, and anxiety and depression. a subset of participants will additionally complete a qualitative interview session to obtain a deeper understanding of sleep disruptors and barriers and facilitators to improving sleep health.


Eligibility criteria:
inclusion criteria: * diagnosed with t1d at least 3 months * receive clinical care at the barbara davis center exclusion criteria: * have an active underlying sleep disorder, such as narcolepsy, insomnia, or untreated sleep apnea * participation in an interventional research protocol * unable to complete study procedures
transcultural multidisciplinary evaluation of patients with hemophili

Conditions: Patients With Haemophilia

Summary: multidisciplinary evaluation of patients with hemophilia spain, el salvador and bolivia. it aims to analyze and evaluate the skeletal muscle of patients affected with hemophilia spain, el salvador and bolivia; describe deficit mobility and muscular strength, depending on the degree of injury, age, presence of inhibitors and the development of physical activity; identify the relationship between the functional deficit by clinical assessment performed with the use of validated measurement scales, the assessment of the degree of injury to specific scales of hemophilia; detect biomechanical alterations of the lower limbs and their impact on gait in patients with hemophilia; and evaluate the factors that influence the perception of illness and quality of life of patients with hemophilia.

descriptive study of joint involvement in patients with hemophilia spain, el salvador and bolivia. descriptive study of abnormal joint mobility and muscle strength as a result of acute conditions or the development of chronic articular sequelae. descriptive study of biomechanical changes in lower limb joints and their impact on gait in patients with hemophilia. descriptive study of the overall articular involvement (crepitus, pain, biomechanical and functional changes) in patients with hemophilia. descriptive study of the relationship between skeletal muscle pathology in patients with hemophilia and their perception of it, and their quality of life.

Eligibility criteria:
inclusion criteria: * patients with hemophilia a and b. * patients of all ages (pediatric, adolescents, youth and adults). * with or without joint involvement clinically diagnosed, and with or without a previous history of hemarthrosis joint load legs. * patients with or without inhibitors. exclusion criteria: * patients without prior ambulation capacity. * patients diagnosed with other congenital coagulopathy (von willebrand disease, etc..). * patients with neurological or cognitive impairments that prevent understanding the questionnaires and physical tests.

Keywords: haemophilia arthropathy range of movement strength proprioception gait quality of life
long term effects of treating submassive pulmonary embolism with ultra-sound accelerated thrombolysis

Conditions: Submassive Pulmonary Embolism

Summary: patients with submassive pulmonary embolism treated with ultra-sound therapy will have an improved right ventricular function 72 hours post treatment.


Eligibility criteria:
inclusion criteria: * patients with acute (\ 0.9 exclusion criteria: * age \> 80 * recent thrombolytic therapy (with in 4 days) * active bleeding or know bleeding diathesis * known coagulopathy (including treatment with vitamin k antagonists) inr \> 3 and/or ptt \> 50 * thrombocytopenia (plt cound \< 100,000) * history of any intracranial or intraspinal surgery, trauma or bleed * intracranial neoplasms, avm, or aneurysm * recent (\< 1 month) gi bleed * recent (\< 3 months) internal eye surgery or hemorrhagic retinopathy * recent (\< 7 days) major surgery, trauma, or obstetrical delivery * renal insufficiency with egfr \< 45 ml/min * known allergy, hypersensitivity, or thrombocytopenia from heparin or tpa * hemodynamic instability defined as need for cardiopulmonay resuscitation, systolic bp \> 90 mm hg for \> 15 min or need for pressor agents to maintain bp \> 90. * severe hypertension (sustained systolic \> 180 mm hg or diastolic \> 90 mm hg. * pregnant patients * known right to left shunt * large (\>10 mm)intracardiac thrombus * use of thrombolytics or glycoprotein iib/iiia antangonists within 3 days of inclusion. * life expectancy \< 30 days

Keywords: submassive pulmonary embolism ultrasonic energy ekosonic endovascular device rv:lv function after pulmonary embolism
lyrica (pregabalin) administered as an add-on therapy for partial seizures (leader).

Conditions: Epilepsy

Summary: the objective of study is to assess the clinical improvement (change in seizure frequency), safety, and tolerability of subjects with partial seizures following adjunctive therapy of pregabalin bid (150 to 600 mg/day titration) in addition to existing standards aeds.


Eligibility criteria:
inclusion criteria: * outpatients equal to or greater than 18 years of age with diagnosis of epilepsy with partial seizures having minimum of two partial seizures during a two month period before the baseline visit * having a clinical history of epilepsy and aed treatment at least 1 year prior to inclusion exclusion criteria: * aed or seizures/epilepsy related exclusions:having a treatable cause of seizures * having absences seizures * having had status epileptics within the year prior to inclusion * having a progressive neurological or systematic disorder * having known significant renal or hepatic dysfunction

Keywords: pregabalin for partial seizures
influence of edible marijuana on endurance exercise performance

Conditions: Endurance Exercise

Summary: lots of people, including athletes and people who like to exercise regularly, enjoy marijuana. some people believe marijuana might improve their ability to exercise. there are no recent, up-to-date scientific studies to suggest that this belief is right or wrong. the goal of this study is to determine the influence of marijuana on exercise performance.

the purpose of the proposed project is to provide athletes and the scientific community with data pertaining to the acute influence of edible marijuana on exercise performance, and the physiological responses to standardized exercise. specifically, the investigators wish to determine: 1. the influence of edible marijuana on cardio-respiratory and metabolic responses to standardized cycle ergometer exercise. 2. the influence of edible marijuana on endurance exercise (time-trial) performance. the investigators wish to determine if edible marijuana, ingested prior to exercise, is ergogenic (improves performance) or ergolytic (decreases performance). the investigators hypothesize that edible marijuana will be ergolytic.

Eligibility criteria:
inclusion criteria: * between the age of 21 and 40. * weigh more than 110 pounds * habitual user of cannabis; average use of thc minimum of once per month during the previous year * prior use of cannabis product containing at least 10 mg of thc with no adverse reaction * habitual exerciser: exercised a minimum of 5 days per week, for a minimum of 30-minutes/session, during the previous year. exclusion criteria: * identification of a contra-indication to exercise during a 12-lead exercise stress test. * pregnant or trying to become pregnant. breastfeeding. * recipient of treatment for psychotic or bipolar disorder during the previous 2 years * recipient of treatment for schizophrenia during the previous 2 years * planned surgery scheduled within 2-weeks of study participation
a study of blood metabolic markers in patients with type 2 diabetes mellitus of different stages

Conditions: Diabetes Mellitus, Type 2

Summary: metabolomics is an emerging "omics" after genomics, transcriptomics and proteomics, which can reflect the physiological state of organisms more directly and accurately. whether metabolite differences exist in patients with type 2 diabetes of different stages and whether such metabolite differences can be used as potential markers have not yet been studied, which is of great significance to explore. in this study, 105 patients with different stages of type 2 diabetes mellitus were enrolled according to the inclusion and exclusion criteria, and the metabolites in the samples were detected by ultra-high performance liquid chromatography coupled with tandem time-of-flight mass spectrometry (uhplc-q-tof ms) after the blood samples were collected, and the corresponding investigative data were collected, and then baseline and demographic analyses, metabolomics data processing, and analysis of the results were carried out to provide a reference for the identification of metabolic markers and to provide a reference for the identification of significant metabolic markers in diabetic patients.


Eligibility criteria:
inclusion criteria: 1. age 18 to 75 years old 2. population of patients with type 2 diabetes mellitus of different stages 3. subjects or legal representatives gave informed consent to voluntarily join the study by signing an informed consent form. exclusion criteria: 1. patients with severe acute underlying brain, cardiac, pulmonary, hepatic, renal and other conditions that the investigator believes to be influential 2. patients diagnosed with any malignancy within the previous 5 years; 3. received any form of oncological treatment including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy and immunotherapy prior to entry for blood sampling; 4. organ transplant recipients or previous non-autologous (allogeneic) bone marrow or stem cell transplant recipients; 5. those who have received blood transfusion therapy 1 month prior to the blood draw; 6. patients with blood-borne diseases such as hepatitis, syphilis, and hiv; 7. patients with other factors that, in the opinion of the investigator, influence the study.

Keywords: diabetes mellitus metabolic marker metabolomics stage of disease
post-operative pain control following shoulder surgery

Conditions: Shoulder Pain

Summary: this study will evaluate overall opioid and non-narcotic analgesic use following surgical treatment for shoulder pathology, and recommend evidence based guidelines for standardized postoperative pain management.

there is currently very limited information in the literature regarding postoperative pain medication consumption following orthopedic shoulder surgery. to fill this knowledge gap, this study will evaluate overall opioid consumption in morphine milligram equivalents following surgical treatment for shoulder pathology.

Eligibility criteria:
inclusion criteria: * opioid-naive adults age 18-90 years old planning to undergo surgical treatment for shoulder pathology with the pi at johns hopkins shoulder service (columbia, odenton clinic sites; howard county general hospital/johns hopkins hospital operative sites) will be included. exclusion criteria: * patients with prior history of opioid misuse, addiction, or chronic pain * patients taking chronic pain medication or have taken opioid medication in the past 3 months will be excluded due to risk of developing drug tolerances that could affect the amount of pain medication consumed after surgery an exception will be made for those who have used narcotic medication for fracture-related events, and expect to undergo surgical treatment for fracture repair (orif or arthroplasty) * patients with bmi \ 39.9 * patients with a history of adverse reaction and/or allergy to oxycodone * patients lacking the ability to consent will also be excluded. * patients whose primary residence is outside the united states will be excluded. * patients who are unable to complete questionnaires due to medical condition, psychiatric illness, or significant language barrier will also be excluded.
cognitive behavioural therapy/metacognitive therapy for low self esteem

Conditions: Psychological Disorders

Summary: the goal for this clinical trial is to explore the effect of cbt/mct on the treatment of low self esteem. 20 patients with low self-esteem will be selected and distributed into two either mct or a cbt we aim in this study to (1) evaluate the accessibility and effectiveness of mct and cbt in treating low self-esteem, (2) investigate the patterns of change and the mechanisms of action involved during treatment, and (3) examine the impact of meta-cognitions and neuropsychologial processes in the treatment response and any relapse prevention of low self-esteem.

the association between low self-esteem and psychiatric disorders indicates that low self-esteem is an important transdiagnostic construct. people who report having a low self-esteem seem to experience more mental health problems and a reduction in quality of life. there have been a few trials considering the effect of cognitive behavioural therapy (cbt) for low self-esteem, however, there are few randomized controlled studies. recently, meta cognitive therapy (mct) has been introduced as a new, specific treatment for mdd, showing promising and lasting results. this treatment approach also has proven more effective than cbt for gad or worry disorder. so far, no study has examined mct for low self-esteem in a randomized controlled trial. for the present clinical trial, 20 patients with low self-esteem will be selected and distributed into two treatment conditions. the first group (n=10) will be treated with mct, whereas the second group (n = 10) will be treated with cbt. the patients will be assessed with different outcome measures at pre-treatment, at the end of treatment, and at six months follow up. in addition, they will also be assessed weekly using various measures. we aim in this study to (1) evaluate the accessibility and effectiveness of mct and cbt in treating low self-esteem, (2) investigate the patterns of change and the mechanisms of action involved during treatment, and (3) examine the impact of meta-cognitions and neuropsychologial processes in the treatment response and any relapse prevention of low self-esteem.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent obtained prior to entry in the study. 2. scores below 15 on the rosenberg self-esteem scale (rse) 3. 18 years or older. exclusion criteria: 1. psychosis 2. bipolar type 1 3. current suicide intent 4. ptsd 5. cluster a or cluster b personality disorder 6. substance dependence

Keywords: low self esteem cognitive behavioural therapy metacognitive therapy depressive symptoms anxiety symptoms
virtual ileostomy versus diverting ileostomy

Conditions: Rectal Cancer

Summary: this study aimed at comparing the comprehensive complication index (cci), readmission rates, postoperative hospitalization days, duration of bearing the stoma (months), hospitalization costs, the number of hospitalizations with virtual ileostomy versus conventional divertingileostomy after total mesorectal excision for rectal cancer.

diverting ileostomy (di) is a common procedure performed in patients undergoing total mesorectal excision for rectal cancer to protect the anastomosis and reduce the risk of complications. although di remains one of the most common methods used in clinical practice to prevent anastomotic leakage, there is still considerable debate in clinical practice about whether to perform a routine ileostomy. despite temporary ileostomy fecal diversion can reduce the development of abdominal abscesses, wound inflammation, peritonitis, and sepsis after the occurrence of al, however, it not only failed to reduce the incidence of al but significantly increased the risk of non-elective readmissions and reinterventions as well as higher total costs. meanwhile, stoma significantly increase the risk of stoma-related complication such as small bowel obstruction, postoperative ileus, dehydration from high-output stoma culminating in acute kidney injury, electrolyte imbalance, stoma stenosis/ necrosis, parastomal hernia, peristomal abscess, and fistula, etc.

Eligibility criteria:
inclusion criteria: * diagnosis of rectal cancer confirmed by pathology * age ≥ 18 years * lap/robot total mesorectal excision (tme) surgical procedures and colon-rectum or colon-anal anastomosis#1.anterior resection (ar/ pme), 2. low anterior resection (lar) , 3.intersphincteric abdominoperineal resection (isr), 4.transanal total mesorectal excision (tatme) * ability to understand the nature and risks of participating in the trial exclusion criteria: * emergency surgery, open surgery * asa score \>3points * patients with combined complete intestinal obstruction * long-term history of using immunosuppressants or glucocorticoids * combined severe cardiac disease: with congestive heart failure or nyha cardiac function ≥ grade 2. patients with a history of myocardial infarction or coronary artery surgery within 6 months before the procedure * chronic renal failure (requiring dialysis or glomerular filtration rate \<30 ml/ min) * intraoperative combined multi-organ resection * combined cirrhosis of the liver * intraoperative findings of incomplete anastomosis and positive insufflation test * missing information

Keywords: virtual ileostomy diverting ileostomy total mesorectal excision
ketamine long therm follow up study

Conditions: Followin Ketamine Treatment

Summary: results of the study and of 5 years follow up of depressed patients who participated in the study during 2014-2015. we will locate the participants and will interview them will use the same questionnaires to evaluate their depressive symptoms. we will also measure the time to relapse.

anamnestic data will be collected from the patients, in addition, depressive symptoms will be measured using montgomery asberg depression scale (madras). in addition, the clinical global severity scale (cgi-s) and clinical global improvement (cgi-i) were performed 2 hours after treatment. in addition, we performed to prolong the time to relapse in this patient.

Eligibility criteria:
inclusion criteria: * participants in the ketamine study exclusion criteria: -

Keywords: major depressive disorder, ketamine, follow up, relapse
comparison of outreach approaches to increase enrollment in a healthy cholesterol study

Conditions: Diabetes

Summary: this study aims to determine the effectiveness of 4 different recruitment techniques for enrollment into a cholesterol study. 2,000 people that meet initial eligibility criteria for the study will be randomized into one of 4 groups and will all receive the same recruitment letter inviting them to participate in the study by enrolling on an online platform. group 1 will receive the recruitment letter in a normal sized envelope, group 2 will receive the recruitment letter in an 8.5 x 11 inch envelope, group 3 will receive a recruitment letter shipped via usps priority mail and a group 4 will receive a recruitment letter with the image of an amazon gift card and told they will receive a $25 gift card if they enroll in the study. all other groups are told that they will receive a $25 check upon enrollment in the study.


Eligibility criteria:
inclusion criteria: * diabetes and or history of cvd * ldl \> or = 130 mg/dl - measured during screening * a prescription filled for statin medication within the last 12 months * medication possession ratio (mpr) \<80% * cvs caremark beneficiary exclusion criteria: * less than 18 years old * contraindication to further statin use or have suffered side effects from statins, such as myopathy * will not or cannot give consent * history of active or progressive liver disease or abnormal liver function tests on baseline screening * currently participating in another clinical trial with related aims * co-morbidities likely to lead to death within a short-period